Hemoperfusion as an Adjuvant Therapy in Maintenance Hemodialysis Patients with Severe COVID-19: A Single Centre Experience

Authors

  • Elizabeth Yasmine Wardoyo Division of Renal Hypertension, Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Anggraini Permata Sari Division of Renal Hypertension, Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Aryan Y Djojo Division of Renal Hypertension, Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Johanes Sarwono Division of Renal Hypertension, Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Md Ikhsan Mokoagow Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Nikko Darnindro Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Jerry Nasarudin Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Marina Epriliawati Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Annela Manurung Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Martha Iskandar Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Krishna Adi Wibisana Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Anak Agung Arie Widyastuti Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia
  • Radhiyatam Mardiyah Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia

Keywords:

hemoperfusion, hemodialysis, COVID-19, cytokines, resin

Abstract

Mortality rate among maintenance hemodialysis (HD) patients with COVID-19 is alarmingly high. In Fatmawati General Hospital, most of HD patients with COVID-19 presented with acute respiratory distress syndrome (ARDS). Hemoperfusion (HP) is a blood purification therapy used to remove cytokines and inflammatory mediators to prevent ARDS worsening and organ failure. We report 6 cases of COVID-19 in maintenance HD patients. HP and HD were performed in two consecutive days when patient developed early ARDS as indicated by inflammatory markers elevation. HP and HD were conducted by using resin-containing cartridge and high-flux dialyzer, respectively, for 4 hours. Improvements in CRP levels, PaO2/FiO2 ratios, and chest X-rays were observed after 2 sessions of HP in most of our patients. Based on our clinical experience, the timing of HP delivery is critical and should be undertaken in the early phase of ARDS, but larger studies are still needed.

Author Biography

Elizabeth Yasmine Wardoyo, Division of Renal Hypertension, Department of Internal Medicine, Fatmawati Hospital, Jakarta, Indonesia

KSM Penyakit Dalam RSUP Fatmawati

References

Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication in critically ill COVID-19. Clin Immunol. 2020;214:108408.

Ronco C, Reis T, de Rosa S. Coronavirus epidemic and extracorporeal therapies in intensive care: Si vis pacem para bellum. Blood Purif. 2020;49:255–8.

Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ill patient during covid-19 pandemic: expert review and recommendation. Blood Purif. 2020;1–11. doi:10.1159/000508125.

Ragab D, Eldin S, Taeimah M, et al. The COVID-19 cytokine storm; What we know so far. Front Immunol. 2020;11:1–4.

Safari S, Salimi A, Zali A, et al. Extracorporeal hemoperfusion as a potential therapeutic option for severe COVID-19 patients: a narrative review. Arch Acad Emerg Med. 2020;8:e67.

Winchester J. Dialysis techniques: hemoperfusion. Replacement of renal function by dialysis. In: Horl W H, Koch K, Lindsay R, Ronco C, Winchester J. Springer; 2004. p. 725–38.

Huang Z, Wang SR, Yang Z, et al. Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2013;17:454–61.

Huang Z, WangSR, Su W, et al. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2010;14:596–602.

Sun S, He L, Bai M, et al. High-volume hemofltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: A controlled pilot study. Ann Saudi Med. 2015;35:352–8.

Ranieri VM. Acute respiratory distress syndrome: The Berlin definition. JAMA. 2012;307:2526–33.

Asgharpour M. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19). BMC Nephrol. 2020;21.

Vardanjani EA. Early hemoperfusion for cytokine removal may contribute to prevention of intubation in patients infected with COVID-19. Blood Purif. 2020; 3848176941:8–11.

Du Y, Qi Z, Ma J, et al. Case report: A patient with COVID-19 who benefited from hemoadsorption. Front Med. 2020;7:1–5.

Mezger M. Sequential use of hemadsorption using Cytosorb® and Biosky® filter-technology in a COVID-19 patient suffering from severe ARDS. Arch Clin Med Case Reports. 2020;04:969–77.

Moradi H, Abbasi S. Hemoperfusion as a supportive treatment in a COVID-19 patient with late pulmonary thromboembolism: A case report. Int Med Case Rep J. 2020;13:341–5.

Shadvar K, Tagizadiyeh A, Gamari AA, et al. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif. 2020;5157663314.

Ankawi G, Fan W, Montin DP. et al. A new series of sorbent devices for multiple clinical purposes: Current evidence and future directions. Blood Purif. 2019;47: 94–100.

Hajian S, Rastgoo N. The effect of hemoperfusion on the recovery of COVID-19 in hospitalized patients; case series and review study. 2021;7:4–7.

Downloads

Published

2022-09-24

How to Cite

Wardoyo, E. Y., Sari, A. P., Djojo, A. Y., Sarwono, J., Mokoagow, M. I., Darnindro, N., Nasarudin, J., Epriliawati, M., Manurung, A., Iskandar, M., Wibisana, K. A., Widyastuti, A. A. A., & Mardiyah, R. (2022). Hemoperfusion as an Adjuvant Therapy in Maintenance Hemodialysis Patients with Severe COVID-19: A Single Centre Experience. Acta Medica Indonesiana, 54(3), 444. Retrieved from https://actamedindones.org/index.php/ijim/article/view/2039

Issue

Vol. 54 No. 3 (2022): Acta Medica Indonesiana

Section

CASE REPORT

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.